Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy

NCT04026178 is registered in ClinicalTrials.gov with Aegerion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04026178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04026178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Phase
Phase 4
Overall status
Completed
Start date
November 14, 2018
Completion date
October 31, 2024
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

generalized lipodystrophy